{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:28:27Z","timestamp":1771824507023,"version":"3.50.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.molmed.2022.07.006","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T02:41:59Z","timestamp":1659494519000},"page":"1082-1099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunogenicity of SARS-CoV-2 vaccines in patients with cancer"],"prefix":"10.1016","volume":"28","author":[{"given":"Helen","family":"Kakkassery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esme","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piers E.M.","family":"Patten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4419-7162","authenticated-orcid":false,"given":"Sheeba","family":"Irshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2022.07.006_bb0005","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2022.07.006_bb0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ccell.2020.09.018","article-title":"COVID-19 and cancer: current challenges and perspectives","volume":"38","author":"Bakouny","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccell.2021.01.001","article-title":"Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients","volume":"39","author":"Abdul-Jawad","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jnci\/djaa168","article-title":"Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis","volume":"113","author":"Zhang","year":"2021","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.molmed.2022.07.006_bb0025","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/978-3-030-63761-3_36","article-title":"Challenges of cellular therapy during the COVID-19 pandemic","volume":"1318","author":"Sahu","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0030","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2352-3026(21)00008-9","article-title":"A rationale to prioritise vaccination of HSCT patients against COVID-19","volume":"8","author":"Leclerc","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/2159-8290.CD-20-1817","article-title":"Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2022.07.006_bb0040","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2022.07.006_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2022.07.006_bb0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2022.07.006_bb0055","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2022.07.006_bb0060","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0065","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s43018-021-00274-w","article-title":"Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.molmed.2022.07.006_bb0070","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2352-3026(21)00199-X","article-title":"Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma","volume":"8","author":"Lim","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0075","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0080","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.annonc.2021.04.019","article-title":"Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors","volume":"32","author":"Barri\u00e8re","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100274","article-title":"Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment","volume":"6","author":"Peeters","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.molmed.2022.07.006_bb0090","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","article-title":"Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer","volume":"7","author":"Massarweh","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0095","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2021.08.035","article-title":"COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: seropositivity and safety. A prospective observational study in Italy","volume":"157","author":"Cavanna","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molmed.2022.07.006_bb0100","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","article-title":"Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors","volume":"27","author":"Shroff","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2022.07.006_bb0105","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer","volume":"39","author":"Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0110","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ccell.2021.08.001","article-title":"Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer","volume":"39","author":"Mairhofer","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0115","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","article-title":"Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer","volume":"39","author":"Addeo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0120","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-21-2439","article-title":"Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution","volume":"27","author":"Di Noia","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2022.07.006_bb0125","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1158\/0008-5472.CAN-21-3554","article-title":"Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in patients with cancer","volume":"81","author":"Figueiredo","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2022.07.006_bb0130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejca.2021.08.007","article-title":"Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy \u2013 a single centre prospective study","volume":"157","author":"Shmueli","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molmed.2022.07.006_bb0135","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.annonc.2021.06.018","article-title":"High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers","volume":"32","author":"Palich","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.annonc.2021.09.009","article-title":"Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study","volume":"33","author":"Nelli","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jtho.2021.10.015","article-title":"Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses","volume":"17","author":"Gounant","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0150","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer","volume":"7","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0155","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2021.10.013","article-title":"Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis","volume":"159","author":"Tran","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molmed.2022.07.006_bb0160","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0165","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2022.07.006_bb0170","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0175","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2022.07.006_bb0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0185","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0190","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2022.07.006_bb0195","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2021.280337","article-title":"BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes","volume":"107","author":"Abdul-Jawad","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.molmed.2022.07.006_bb0200","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2021.5437","article-title":"Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations","volume":"8","author":"Mair","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0205","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0210","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","article-title":"Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein","volume":"26","author":"Zost","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2022.07.006_bb0215","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2022.07.006_bb0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.21.01891","article-title":"Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX Cohort Study","volume":"40","author":"Naranbhai","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0225","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","volume":"35","author":"Stampfer","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2022.07.006_bb0230","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2022.07.006_bb0235","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.molmed.2022.07.006_bb0240","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2022.07.006_bb0245","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ccell.2021.10.003","article-title":"Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer","volume":"39","author":"McKenzie","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0250","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","article-title":"mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial","volume":"22","author":"Oosting","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0255","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s43018-022-00364-3","article-title":"Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study","volume":"3","author":"Lim","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.molmed.2022.07.006_bb0260","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccell.2021.12.002","article-title":"Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer","volume":"40","author":"Naranbhai","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0265","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-022-00610-8","article-title":"COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety","volume":"19","author":"Fendler","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0270","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mco2.110","article-title":"SARS-CoV-2 Omicron variant: characteristics and prevention","volume":"2","author":"He","year":"2021","journal-title":"MedComm"},{"key":"10.1016\/j.molmed.2022.07.006_bb0275","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2021.12.014","article-title":"COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer","volume":"40","author":"Zeng","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0280","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2022.07.006_bb0285","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ccell.2021.09.015","article-title":"Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma","volume":"39","author":"Aleman","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ccell.2021.11.006","article-title":"Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer","volume":"40","author":"Shapiro","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0295","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjh.17877","article-title":"T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies","volume":"196","author":"Marasco","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0300","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/bloodadvances.2021006101","article-title":"Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"6","author":"Jim\u00e9nez","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.molmed.2022.07.006_bb0305","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2022.07.006_bb0310","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0315","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2022.07.006_bb0320","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/eji.200737768","article-title":"Polyfunctional T cell responses are a hallmark of HIV-2 infection","volume":"38","author":"Duvall","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0325","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.17568","article-title":"Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia","volume":"194","author":"Harrington","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0330","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1038\/s41375-021-01300-7","article-title":"Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms","volume":"35","author":"Harrington","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2022.07.006_bb0335","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2022.07.006_bb0340","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clim.2006.05.002","article-title":"Long-lived effector\/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients","volume":"120","author":"Yang","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0345","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.2021013429","article-title":"Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma","volume":"139","author":"En\u00dfle","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2022.07.006_bb0350","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2022.07.006_bb0355","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","article-title":"Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action","volume":"6","author":"Heinz","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.molmed.2022.07.006_bb0360","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0365","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.chom.2022.01.003","article-title":"Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections","volume":"30","author":"Terreri","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.molmed.2022.07.006_bb0370","doi-asserted-by":"crossref","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals after mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0375","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1158\/2159-8290.CD-21-1072","article-title":"Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors","volume":"11","author":"Waldhorn","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2022.07.006_bb0380","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3390\/cancers14081962","article-title":"Immunogenicity of COVID-19 vaccinations in hematological patients: 6-month follow-up and evaluation of a 3rd vaccination","volume":"14","author":"Schubert","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2022.07.006_bb0385","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaoncol.2021.6764","article-title":"Assessment of response to a third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment","volume":"8","author":"Rottenberg","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0390","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41467-022-28578-0","article-title":"Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies","volume":"13","author":"Re","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2022.07.006_bb0395","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1016\/S2352-3026(21)00274-X","article-title":"Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT","volume":"8","author":"Redjoul","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0400","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejca.2021.12.025","article-title":"Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer","volume":"163","author":"Debie","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molmed.2022.07.006_bb0405","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jamaoncol.2021.7777","article-title":"SARS-CoV-2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents","volume":"8","author":"Fenioux","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0410","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1470-2045(21)00715-4","article-title":"Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer","volume":"23","author":"Ligumsky","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0415","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/bjh.17982","article-title":"Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response","volume":"196","author":"Reimann","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0420","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ccell.2021.09.001","article-title":"Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0425","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ccell.2021.12.013","article-title":"Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer","volume":"40","author":"Fendler","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0430","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(22)00147-7","article-title":"Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer","volume":"399","author":"Fendler","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2022.07.006_bb0435","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1056\/NEJMoa2201688","article-title":"Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"386","author":"Magen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2022.07.006_bb0440","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10238-021-00746-4","article-title":"Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine","volume":"22","author":"Gavriatopoulou","year":"2021","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.molmed.2022.07.006_bb0445","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ccell.2022.04.016","article-title":"Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients \u2013 COVIDOUT study","volume":"40","author":"Sch\u00f6nlein","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2022.07.006_bb0450","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s43018-021-00191-y","article-title":"Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy","volume":"2","author":"Thakkar","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.molmed.2022.07.006_bb0455","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2022.07.006_bb0460","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1080\/10428194.2021.1957877","article-title":"Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies","volume":"62","author":"Re","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.molmed.2022.07.006_bb0465","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.molmed.2022.07.006_bb0470","doi-asserted-by":"crossref","first-page":"20499","DOI":"10.1038\/s41598-021-00007-0","article-title":"CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties","volume":"11","author":"Vlaming","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2022.07.006_bb0475","article-title":"Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study","author":"Madelon","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.molmed.2022.07.006_bb0480","series-title":"Kelley and Firestein\u2019s Textbook of Rheumatology","first-page":"1044","article-title":"Novel intra-cellular targeting agents in rheumatic disease","author":"Cohen","year":"2017"},{"key":"10.1016\/j.molmed.2022.07.006_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0490","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00109-020-01958-z","article-title":"Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis","volume":"98","author":"Lechner","year":"2020","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.molmed.2022.07.006_bb0495","doi-asserted-by":"crossref","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","article-title":"Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"373","author":"Corbett","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.molmed.2022.07.006_bb0500","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0505","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","article-title":"Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours","volume":"22","author":"Oosting","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0510","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.annonc.2021.04.020","article-title":"Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients","volume":"32","author":"Palich","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0515","article-title":"Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy","author":"Walle","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.molmed.2022.07.006_bb0520","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"Avivi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0525","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.17743","article-title":"Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients","volume":"195","author":"Benda","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0530","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia","volume":"107","author":"Benjamini","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.molmed.2022.07.006_bb0535","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bjh.17644","article-title":"Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms","volume":"194","author":"Chowdhury","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0540","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejca.2021.05.036","article-title":"High levels of anti-SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine","volume":"154","author":"Fong","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molmed.2022.07.006_bb0545","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2022.07.006_bb0550","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.2217\/fon-2021-0597","article-title":"Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy","volume":"17","author":"Karacin","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0555","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejca.2022.01.019","article-title":"Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events \u2013 a retrospective cohort study","volume":"165","author":"Mair","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molmed.2022.07.006_bb0560","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.molmed.2022.07.006_bb0565","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"Parry","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.molmed.2022.07.006_bb0570","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-021-01130-1","article-title":"Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2022.07.006_bb0575","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2021.06.002","article-title":"The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: a monocentric experience","volume":"154","author":"Revon-Riviere","year":"2021","journal-title":"Eur. J. Cancer"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491422001861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491422001861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:26:13Z","timestamp":1761463573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491422001861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":115,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1471491422001861"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2022.07.006","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of SARS-CoV-2 vaccines in patients with cancer","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2022.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}